469 related articles for article (PubMed ID: 27121778)
1. Rituximab in the treatment of inflammatory myopathies: a review.
Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
[TBL] [Abstract][Full Text] [Related]
2. Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies.
de Souza FHC; Miossi R; de Moraes JCB; Bonfá E; Shinjo SK
Adv Rheumatol; 2018 Sep; 58(1):31. PubMed ID: 30657080
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
[TBL] [Abstract][Full Text] [Related]
4. Classification, diagnosis, and management of idiopathic inflammatory myopathies.
Lazarou IN; Guerne PA
J Rheumatol; 2013 May; 40(5):550-64. PubMed ID: 23504386
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
[TBL] [Abstract][Full Text] [Related]
6. Biologic predictors of clinical improvement in rituximab-treated refractory myositis.
Reed AM; Crowson CS; Hein M; de Padilla CL; Olazagasti JM; Aggarwal R; Ascherman DP; Levesque MC; Oddis CV;
BMC Musculoskelet Disord; 2015 Sep; 16():257. PubMed ID: 26382217
[TBL] [Abstract][Full Text] [Related]
7. The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature.
Barsotti S; Cioffi E; Tripoli A; Tavoni A; D'Ascanio A; Mosca M; Neri R
Reumatismo; 2018 Jul; 70(2):78-84. PubMed ID: 29976041
[TBL] [Abstract][Full Text] [Related]
8. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
[TBL] [Abstract][Full Text] [Related]
9. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapy in the idiopathic inflammatory myopathies.
Khoo T; Limaye V
Rheumatol Int; 2020 Feb; 40(2):191-205. PubMed ID: 31680207
[TBL] [Abstract][Full Text] [Related]
11. [The shades of anti-Jo1 positive antisynthetase syndrome in a Hungarian cohort].
Szabó K; Nagy-Vincze M; Bodoki L; Hodosi K; Dankó K; Griger Z
Orv Hetil; 2016 Apr; 157(15):575-83. PubMed ID: 27039996
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.
Zhen C; Hou Y; Zhao B; Ma X; Dai T; Yan C
Front Immunol; 2022; 13():1051609. PubMed ID: 36578492
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for Inflammatory Myopathies in a Colombian Cohort.
Santos VA; Aragón CC; Posso-Osorio I; Naranjo-Escobar J; Milisenda JC; Obando MA; Barrera T; Zamorano L; Hormaza-Jaramillo A
J Clin Rheumatol; 2021 Sep; 27(6S):S232-S235. PubMed ID: 33337818
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Unger L; Kampf S; Lüthke K; Aringer M
Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in polymyositis and dermatomyositis.
Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A
Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825
[TBL] [Abstract][Full Text] [Related]
16. Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.
Mao MM; Xia S; Guo BP; Qian WP; Zheng ZX; Peng XM; Chen RC; Luo Q; Han Q
Respir Med; 2020 Oct; 172():105983. PubMed ID: 33032789
[TBL] [Abstract][Full Text] [Related]
17. [How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies].
Sibilia J; Chatelus E; Meyer A; Gottenberg JE; Sordet C; Goetz J
Presse Med; 2010 Oct; 39(10):1010-25. PubMed ID: 20655695
[TBL] [Abstract][Full Text] [Related]
18. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
Oddis CV; Reed AM; Aggarwal R; Rider LG; Ascherman DP; Levesque MC; Barohn RJ; Feldman BM; Harris-Love MO; Koontz DC; Fertig N; Kelley SS; Pryber SL; Miller FW; Rockette HE;
Arthritis Rheum; 2013 Feb; 65(2):314-24. PubMed ID: 23124935
[TBL] [Abstract][Full Text] [Related]
20. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies.
Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE
Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
